MYD88 L265P Mutation Detection by PCR, Quantitative

Casandra

Casandra Test Code AR00309Version 1 (DRAFT)

Performing Lab

Lab ARUP LaboratoriesLab Test ID 2009318CPT Code 81305

MYD88 L265P Mutation Detection by PCR, Quantitative

Also known as: MYD88

Clinical Use

Order Test

Use

This test is useful in distinguishing lymphoplasmacytic lymphoma (LPL) from other low-grade B-cell lymphoproliferative disorders which may be in the differential diagnosis. It can also be used in monitoring patients with an LPL diagnosis and a previously identified MYD88 L265P mutation. The MYD88 L265P mutation is present in the majority of cases of lymphoplasmacytic lymphoma and, less commonly, in other B-cell lymphoproliferative disorders.

Special Instructions

If multiple specimens (blocks or slides) are sent to ARUP, they must be accompanied by an order comment indicating the specimen most appropriate for testing or individual orders for each sample. A Pathologist Block Selection Fee applies if ARUP pathologist chooses the specimen. Multiple specimens without clear instructions will be held until clarification.

Limitations

Mutations in other locations within the MYD88 gene or mutations in other genes will not be detected. The limit of detection for this test is 0.2 percent mutant alleles, corresponding to 0.4 percent heterozygous mutant cells. Results must be interpreted within the context of clinical data and should not be used alone for a diagnosis of malignancy. This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US FDA.

Test Details

New York Approved